Atossa Therapeutics (NASDAQ:ATOS - Get Free Report) posted its earnings results on Monday. The company reported ($0.06) earnings per share (EPS) for the quarter, Yahoo Finance reports.
Atossa Therapeutics Price Performance
Shares of ATOS traded down $0.16 on Tuesday, reaching $1.84. 3,553,833 shares of the stock traded hands, compared to its average volume of 1,050,380. The firm has a market cap of $230.55 million, a price-to-earnings ratio of -7.67 and a beta of 1.19. Atossa Therapeutics has a 12 month low of $0.59 and a 12 month high of $2.11. The stock's 50-day moving average price is $1.17 and its 200-day moving average price is $0.90.
Analyst Upgrades and Downgrades
Several equities analysts recently weighed in on the company. StockNews.com cut Atossa Therapeutics from a "hold" rating to a "sell" rating in a research report on Monday, March 18th. HC Wainwright reissued a "buy" rating and issued a $4.00 price objective on shares of Atossa Therapeutics in a research report on Tuesday. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Atossa Therapeutics in a research report on Friday, January 12th.
Read Our Latest Stock Analysis on ATOS
Hedge Funds Weigh In On Atossa Therapeutics
A number of hedge funds have recently made changes to their positions in the business. Millennium Management LLC bought a new position in shares of Atossa Therapeutics during the 2nd quarter worth approximately $1,673,000. Renaissance Technologies LLC lifted its holdings in shares of Atossa Therapeutics by 79.5% during the first quarter. Renaissance Technologies LLC now owns 2,100,492 shares of the company's stock valued at $2,626,000 after acquiring an additional 930,152 shares during the period. Bank of Montreal Can acquired a new stake in shares of Atossa Therapeutics in the 2nd quarter valued at $365,000. GSA Capital Partners LLP grew its holdings in shares of Atossa Therapeutics by 29.3% in the 4th quarter. GSA Capital Partners LLP now owns 449,082 shares of the company's stock worth $395,000 after purchasing an additional 101,690 shares during the last quarter. Finally, State Street Corp increased its position in shares of Atossa Therapeutics by 4.2% during the 1st quarter. State Street Corp now owns 2,233,010 shares of the company's stock worth $2,791,000 after purchasing an additional 90,960 shares in the last quarter. Institutional investors and hedge funds own 12.74% of the company's stock.
About Atossa Therapeutics
(
Get Free Report)
Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.
See Also
Before you consider Atossa Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Atossa Therapeutics wasn't on the list.
While Atossa Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
